Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. uri icon

authors

  • Madero-Marroquin, Rafael
  • Odenike, Olatoyosi
  • Stock, Wendy
  • Larson, Richard A
  • Patel, Anand A
  • Dworkin, Emily
  • Weiner, Howard
  • Saygin, Caner
  • Mariam Nawas, MD
  • Drazer, Michael W
  • DuVall, Adam S
  • Kosuri, Satyajit
  • Thirman, Michael J

publication date

  • March 5, 2024